CoChat

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

Burova, Elena, Hermann, Aynur, Waite, Janelle, Potocky, Terra, Lai, Venus, Hong, Seongwon, Liu, Matt, Allbritton, Omaira, Woodruff, Amy, Wu, Qi, D’Orvilliers, Amanda, Garnova, Elena, Rafique, Ashique, Poueymirou, William, Martin, Joel, Huang, Tammy, Skokos, Dimitris, Kantrowitz, Joel, Popke, Jon, Mohrs, Markus, MacDonald, Douglas, Ioffe, Ella, Olson, William, Lowy, Israel, Murphy, Andrew, Thurston, Gavin · 2017 · Molecular Cancer Therapeutics
Cited by 114

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The Programmed Death-1 (PD-1) receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Clinical antibodies blocking the interaction between PD-1 and PD-L1 restore the cytotoxic function of tumor antigen-specific T cells, yielding durable objective responses in multiple cancers. This report describes the preclinical characterization of REGN2810, a fully human hinge-stabilized IgG4(S228P) high-affinity anti–PD-1 antibody that potently blocks PD-1 interactions with PD-L1 and PD-L2. REGN2810 was characterized in a series of binding, blocking, and functional cell-based assays, and preclinical in vivo studies in mice and monkeys. In cell-based assays, REGN2810 reverses PD-1–dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells. To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1. In these mice, REGN2810 binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 was performed in cynomolgus monkeys. High doses of REGN2810 were well tolerated, without adverse immune-related effects. These preclinical studies validate REGN2810 as a potent and promising candidate for cancer immunotherapy. Mol Cancer Ther; 16(5); 861–70. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0665

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 114

Metadata

Authors
Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., D’Orvilliers, A., Garnova, E., Rafique, A., Poueymirou, W., Martin, J., Huang, T., Skokos, D., Kantrowitz, J., Popke, J., Mohrs, M., MacDonald, D., Ioffe, E., Olson, W., Lowy, I., Murphy, A., & Thurston, G.
Venue
Molecular Cancer Therapeutics
Published
2017-05-01
Volume
16
Issue
5
Pages
861-870
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2593714049
Cited by
114
References
16
FWCI
4.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0665
The paper
Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., D’Orvilliers, A., Garnova, E., Rafique, A., Poueymirou, W., Martin, J., Huang, T., Skokos, D., Kantrowitz, J., Popke, J., . . . Thurston, G. (2017). Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.